Knowledge Exchange by ISID

TB is a re-emerging disease. According to the WHO, about a quarter of the global population is estimated to be infected with Mycobacteria tuberculosis. About 5-10% of those infected develop symptomatic TB which they can spread to others. In 2022, TB was the second leading infectious cause of death after COVID-19. TB is preventable and curable. TB can be prevented by use of the vaccine BCG. BCG is usually given at birth as part of routine immunization for children in most low resource settings. Antibiotics are available for the treatment of TB, however the development of Multidrug Resistant TB may necessitate use of second line antibiotics in the treatment of TB. Prevention, early diagnosis and treatment of at-risk groups like those co-infected with HIV is necessary for effective control and management of TB.

This webinar will focus on following the patient journey and increasing:

• Chikungunya disease awareness 
• Chikungunya risks 
• Chikungunya prevention / mitigation
• Review of recent outbreaks
• Impact of recent outbreaks and the profound impact on health systems
• Increased risks associated with global warming and climate change

Chikungunya virus (CHIKV) has been identified as a priority pathogen and as an emerging infectious disease requiring special action by the World Health Organization (WHO). Its reemergence is rapid and geographically extensive, it has caused large outbreaks with high attack rates in Africa, Asia, Europe, Americas, and islands in the Indian and Pacific Oceans. 
Although Chikungunya fever is a self-limiting disease and the associated fatality rate is low, chikungunya-related death has been reported in certain populations, specially in people with pre-existing conditions.

Since there is no specific treatment, there is a medical need for prophylaxis against CHIKV infection. Some promising preclinical and clinical vaccine candidates have been developed during recent years, involving a wide range of technology platforms including: inactivated Viruses and Subunit Vaccines, Live-Attenuated Viruses, Virus-Like Particles, Viral Vector Vaccines and Nucleic Acid-Based Vaccines. Advancing developments in current candidates in the pipeline as well as further R&D work required is crucial as it is understanding the epidemiological gaps and modeling needs to perform further efficacy trials; in this webinar some of these aspects will be presented and questions welcomed from the audience.

Sepsis is the body’s extreme response to an infection. Despite recent progress in the understanding and treatment of sepsis, few data or recommendations exist that detail effective approaches to sepsis care in resource-limited low-income and middle-income countries. Although few data exist on the burden of sepsis in LMICs, the prevalence of HIV and other comorbid conditions in some LMICs suggest that sepsis is a substantial contributor to mortality in these regions. In well-resourced countries, sepsis management relies on protocols and complex invasive technologies not widely available in most LMICs. However, key concepts and components of sepsis management are potentially translatable to resource-limited environments. Health personnel in LMICs should learn how to recognize sepsis and the importance of early and appropriate antibiotic use and laboratory diagnosis of sepsis. Simple and low-cost standardized laboratory testing should be emphasized to allow accurate diagnosis, prognosis, and monitoring of treatment response. Evidence-based interventions and treatment algorithms tailored to LMIC ecology and resources should thus be developed and validated.

Dengue is a public health problem that continues to increase globally. Dengue is spreading to new areas, including Europe, with some countries reporting first-time local transmission cases. As treatment options are limited, public health control measures include strengthening national programs to meet objectives through coordinated efforts inside and outside the health sector. There is currently no definitive treatment for dengue; only supportive treatment is available for patients with the infection.

However, there have been recent advances in the development of promising drugs for dengue therapeutics, including direct antivirals and host-targeted drugs for reducing inflammation and vascular pathologies. Developing novel vector control methods and new approaches to case management are important for prevention and control. A safe and efficacious vaccine remains the foundation of a comprehensive countermeasure strategy. Recent advances in host-targeted pathways and novel therapeutic approaches are crucial and should be integrated into the research agenda with current vector control tools and vaccination developments.

Chikungunya is a mosquito transmitted alpha virus. Since its emergence in Africa, the global distribution is rapidly expanding, the disease has spread to most continents. The spread to new areas is possible due to the travel of infected persons and presence of mosquitoes in these new areas that are able to spread the disease. The spread has been found to be more in tropical and sub-tropical countries. Several data driven empirical approaches and spatiotemporal forecasting have been used to forecast chikungunya spread in places like the Americas. Some of these forecasting methods have been used to predict infected cases and locations based on machine learning. Although there is currently no specific treatment and vaccine in use, there are several vaccine candidates in different stages of clinical trials that have shown promising results.

Please take 2 minutes after the webinar to fill out our evaluation form: https://isid.typeform.com/to/UVicf1XR

Chikungunya is a mosquito borne viral disease caused by the Chikungunya virus (CHIKV), a Togaviridae virus, and is transmitted by Aedes mosquitoes. Clinical symptoms include acute onset of fever, debilitating joint and muscle pain, headache, nausea, and rash, potentially developing into long-term serious health impairments. Chikungunya virus causes clinical illness in 72 – 92% of infected human around 4 to 7 days after an infected mosquito bite. Complications resulting from the disease include visual, neurological, heart and gastrointestinal manifestations; fatalities have been reported in elderly people at higher risk.
 
Chikungunya outbreaks have been reported in Asia, Africa, the Americas and recently in Europe. Both the medical and economic burden are expected to grow as the CHIKV primary mosquito vectors continue their geographic spread Although there are some candidate vaccines in clinical trials none are licensed. Therefore, chikungunya shall remain a major public health threat.

According to the WHO, the incidence of dengue has increased considerably in recent decades. Dengue is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, Southeast Asia, and the Western Pacific. Asia bears about 70% of the global burden of dengue. There is no specific treatment for dengue. So far only one dengue vaccine CYD-TDV has been licensed for use. It is currently in use in about 20 countries globally. There are several candidate vaccines in different stages of development, some are currently in various stages of Clinical Trials. Several challenges have been faced in the development of the vaccines, some of which include the nature of the virus itself that has four serotypes and the immune response to the vaccine.